OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis. - Wikidata - wikimedia - TriplyDB

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

http://www.wikidata.org/entity/Q37273138

about

Modulation of GITR for cancer immunotherapy Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications Science gone translational: the OX40 agonist story Suppression, subversion and escape: the role of regulatory T cells in cancer progression Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors Control of established melanoma by CD27 stimulation is associated with enhanced effector function and persistence, and reduced PD-1 expression of tumor infiltrating CD8(+) T cells The "Trojan Horse" approach to tumor immunotherapy: targeting the tumor microenvironment.Control of immunity by the TNFR-related molecule OX40 (CD134)Antibody-based immunotherapy for malignant glioma.Redirecting the immune response: role of adoptive T cell therapy.Immunomodulatory effects of cyclophosphamide and implementations for vaccine design.OX40 facilitates control of a persistent virus infection.A therapeutic OX40 agonist dynamically alters dendritic, endothelial, and T cell subsets within the established tumor microenvironment.HDAC11 plays an essential role in regulating OX40 ligand expression in Hodgkin lymphoma.Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination Intratumoral temozolomide synergizes with immunotherapy in a T cell-dependent fashion.Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer.Selective targeting of Toll-like receptors and OX40 inhibit regulatory T-cell function in follicular lymphoma Agonist antibodies to TNFR molecules that costimulate T and NK cells Combination of alphavirus replicon particle-based vaccination with immunomodulatory antibodies: therapeutic activity in the B16 melanoma mouse model and immune correlates.TNF superfamily protein-protein interactions: feasibility of small- molecule modulation Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Immunosuppressive tumor microenvironment in cervical cancer patients Immune microenvironments in solid tumors: new targets for therapy.New insights on OX40 in the control of T cell immunity and immune tolerance in vivo Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido.Whole cell vaccines--past progress and future strategies.Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.Comprehensive analysis of current approaches to inhibit regulatory T cells in cancer.Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer Current clinical trials testing combinations of immunotherapy and radiation.Induction of tumoricidal function in CD4+ T cells is associated with concomitant memory and terminally differentiated phenotype Doxil synergizes with cancer immunotherapies to enhance antitumor responses in syngeneic mouse models.Requirement for innate immunity and CD90⁺ NK1.1⁻ lymphocytes to treat established melanoma with chemo-immunotherapy.Profound impairment of adaptive immune responses by alkylating chemotherapy New insights into the role of the immune microenvironment in breast carcinoma.Advances in targeting cell surface signalling molecules for immune modulation Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication.

P2860

Q26853557-16816CE6-79A3-4ADB-9642-8B0B4044141E Q26996518-1DA5AA74-7ED3-414F-8743-A792AB5EDC2C Q27022436-4C659146-C64B-4970-988E-68186E23DEF5 Q27026151-A5EADCD3-6126-488E-9E62-8BC72AD024C1 Q28072532-0F0CA93E-DD73-4C3D-9D5C-9854F132388B Q30430481-C6A93065-0D3D-4E15-9708-A2951A1ADA52 Q33736218-B4C27438-6D07-425A-B4E5-BB066A43055F Q33899607-AAB81428-0DFA-4D1D-9FD6-168CC7800BA8 Q34120472-442FD9A9-3E70-4F13-95F9-E8D24D367EDE Q34123238-66734C95-444D-4568-9844-66C1D5BE0087 Q34187201-8EB2AC4C-E59C-44B2-BD3A-7A347EDBE223 Q34411863-5BA63AB3-0B14-4DDA-98FD-07956209663C Q34682173-E5BDF351-D522-4A97-BF4F-A88319B9E51A Q34707183-C6C6FC1E-3BC0-4247-B768-AF2959E830E9 Q34759603-3AC91EE1-0CAA-4E64-ADEC-11A10F43D4B2 Q34775318-627E27FF-26DE-4DF2-9E48-03D31499DBD8 Q34801069-4DA69B03-127B-4C5C-A2D5-DCE623AEBC8E Q35107110-7D77672C-A553-4D15-B492-15E8B4154BA5 Q35154940-91C0182A-36AD-495B-B92F-D46D5C9BAD4D Q35427446-235C500A-E374-4D85-A4C5-197E6DF356B4 Q35527105-A0187A00-C11B-43AB-99B2-4C37C3766449 Q35534271-2541A4BA-0326-484A-8473-498D7C548B40 Q35580479-9418CAA7-BB7E-434F-9EB8-BE674B2A5FF0 Q35603131-F191527E-AF5B-454C-BAF4-7F610F23B44E Q35642044-4317300A-6640-4091-A2B8-5F69D5361B07 Q35685810-4BFFCEEB-F510-4E92-8FF1-0DB9889C645B Q35753251-B157F6AF-DF54-4B09-B70E-77D073600579 Q35975381-2C3BBFBF-9B13-4EB8-9F1D-E95C325B3B05 Q35982675-C9A16960-9AE6-459C-9E0A-B9FFFC368266 Q36057441-43277E32-FBAD-411F-BB5C-8BCA45990936 Q36193004-2FE98233-41A3-4A01-BD8C-683519EFEBD3 Q36268306-E406AF94-E6F0-4C6C-BB82-D7E71E16F1A5 Q36340873-06BB1B81-395F-4DE8-88F4-D95F661479AC Q36360125-83D9AB0F-FB37-4D9F-980E-B822540B7152 Q36401731-C383BEBF-DDF6-4B82-9C93-B2E7631B134B Q36922577-A6B6938C-06F4-467E-B5B8-AB5CF266CE34 Q36938731-0EB22912-F53E-4815-A389-A7DA694286C2 Q36973787-071A5808-ABB1-4F0E-AA05-14410E3643B6 Q37017190-097198C9-E65A-4715-A3A4-6FAC9A9173CD Q37055402-8721E5D2-A069-45EE-8674-73EF7DC63D13

P2860

OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis.

http://www.wikidata.org/entity/Q37273138

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 04 May 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@en

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@nl

type

label

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@en

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@nl

prefLabel

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@en

OX40 engagement and chemothera ...... t regulatory T cell apoptosis.

@nl

P1433

Q37273138-42EE278E-0A6C-486F-9BCF-3475C5FBB414

P1476

Q37273138-4738FB01-3A84-4671-9D6F-C4331BEDE891

P2093

Q37273138-017C5991-BC15-45CE-8F40-B288BF920D82

Q37273138-0F45B5A8-7C14-45E3-AF26-17E26C33FA55

Q37273138-37B6AC92-2C64-4BD2-BE91-9B5B2C6D9079

Q37273138-55807070-6921-4F99-8C5B-04BBE44D3D85

Q37273138-61A54466-F45B-406A-B335-2A3E3537A2DC

Q37273138-947B72D3-B88E-4E8D-A499-BED738A1323C

Q37273138-B59D9885-F309-4B3C-A732-226B03122AE7

Q37273138-F039F451-1FD5-482B-B708-67C16C609FAF

P2860

Q37273138-0209669B-9E30-442B-BD51-72C847248669

Q37273138-02B1BC5F-4837-4FB2-A7AB-59B60AADB13D

Q37273138-031E7142-E316-454E-B04A-B52D758AC1E0

Q37273138-041DA246-9C60-44EB-8262-1886301289C1

Q37273138-0A5695EA-E144-4D4E-892D-F9DD96A7A19B

Q37273138-0EE1A975-E204-464B-9103-086452111BD3

Q37273138-1264FD16-F249-4DAC-9E9C-D3196B5B19AF

Q37273138-2B23355D-1E48-4C83-A59C-48AE905C808A

Q37273138-2D537FB9-DEF4-496E-AEF0-D0023D6ADFE8

Q37273138-30D72CBC-92AA-4405-95DA-857C81061B9B

P304

Q37273138-70A43FA3-123C-413F-8E0B-0250C4F8B8F0

P31

Q37273138-A2509D3B-6448-4A2D-91D2-FCC6FF85F2E2

P356

Q37273138-39763C04-0499-4351-97E8-0DB513B6075B

P407

Q37273138-3D7F77D5-0668-4D18-BBC8-3EEA39229E0A

P433

Q37273138-69C514E9-E4B1-49CA-8712-8402D0EE950E

P478

Q37273138-23F5BE22-664F-4C9E-AA9A-823066112895

P50

Q37273138-8FB48114-F92A-46D9-96AC-F3E41969E2BA

P577

Q37273138-76F15065-4630-4330-9314-4BB0595CB6C3

P5875

Q37273138-187E8EA1-C387-4F60-AB7B-7377D0F9A9AA

P698

Q37273138-A22BC52C-976B-49CD-8B54-96848EE25656

P921

Q37273138-7B6A8331-DD23-465F-AA2A-815ECB8BCABC

Q37273138-945334A6-BC99-4429-B1D6-76B1230413DC

P932

Q37273138-E89E4F4B-D647-4498-A130-A2ED36A34C4C

P356

P1433

Journal of Experimental Medicine

P1476

OX40 engagement and chemothera ...... nt regulatory T cell apoptosis

@en

P2093

Alan N Houghton

http://www.w3.org/2001/XMLSchema#string

Alexander M Lesokhin

http://www.w3.org/2001/XMLSchema#string

Andrew D Weinberg

http://www.w3.org/2001/XMLSchema#string

Daniel Hirschhorn-Cymerman

http://www.w3.org/2001/XMLSchema#string

Francesca Avogadri

http://www.w3.org/2001/XMLSchema#string

Gabrielle A Rizzuto

http://www.w3.org/2001/XMLSchema#string

Jedd D Wolchok

http://www.w3.org/2001/XMLSchema#string

Taha Merghoub

http://www.w3.org/2001/XMLSchema#string

P2860

Central role of defective interleukin-2 production in the triggering of islet autoimmune destruction

TNF/TNFR family members in costimulation of T cell responses

Regulatory T cell lineage specification by the forkhead transcription factor foxp3

Robust B cell immunity but impaired T cell proliferation in the absence of CD134 (OX40)

A function for interleukin 2 in Foxp3-expressing regulatory T cells

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

Regulatory T cells and immune tolerance

CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production

Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy

At-risk and recent-onset type 1 diabetic subjects have increased apoptosis in the CD4+CD25+ T-cell fraction.

P304

1103-1116

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1084/JEM.20082205

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

206

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-05-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24400888

http://www.w3.org/2001/XMLSchema#string

P698

19414558

http://www.w3.org/2001/XMLSchema#string

P921

apoptotic process

P932

2715041

http://www.w3.org/2001/XMLSchema#string